peptidesinstitute.org
BONE HEALTH

Teriparatide

Teriparatide (PTH 1-34 / Forteo)

Anabolic Parathyroid Hormone Fragment for Bone Health

Buy Teriparatide
Based on the combined works of Dr. William A. Seeds and Dr. Ian W. Hamley
— authoritative voices whose published research informed this article

The information on this page is compiled from peer-reviewed research and is provided for educational and research purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Peptides discussed here may not be approved for human use in your jurisdiction. Always consult a qualified healthcare provider before starting, stopping, or modifying any health protocol.

Overview

What is Teriparatide?

Teriparatide is the recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34), the biologically active N-terminal fragment of the 84-amino-acid endogenous parathyroid hormone. It is produced via recombinant DNA technology in Escherichia coli. Teriparatide is the only FDA-approved anabolic (bone-building) agent for osteoporosis treatment in the United States, available under the brand names Forteo and Bonsity, and represents a fundamentally different pharmacological approach to bone loss compared to antiresorptive agents such as bisphosphonates and denosumab.

The distinction between teriparatide's anabolic effects and the catabolic effects of endogenous PTH overproduction lies entirely in the pattern of exposure. Chronic continuous elevation of parathyroid hormone (as occurs in primary hyperparathyroidism) drives net bone resorption and cortical bone thinning. Intermittent administration of low-dose teriparatide (a daily subcutaneous injection that produces a transient pulse of PTH activity) produces the opposite effect: net bone formation exceeds resorption [1]. The mechanism involves direct stimulation of osteoblasts (bone-forming cells), suppression of osteoblast apoptosis, activation of resting bone surfaces previously not undergoing remodeling, and indirect modulation of osteoclast activity. The result is an increase in both trabecular bone volume and cortical bone thickness.

Clinical evidence for teriparatide is robust. In the pivotal randomized controlled trial in postmenopausal women with prior vertebral fractures (n=1,637), 20 mcg daily teriparatide over a median of 21 months reduced new vertebral fracture risk by 65% and nonvertebral fragility fracture risk by 53% [1], while increasing lumbar spine bone mineral density (BMD) by 9% and femoral neck BMD by 3%. A 2024 systematic review and meta-analysis comparing teriparatide with other anabolic agents confirmed its substantial benefits in lumbar spine and hip BMD gains and fracture risk reduction, particularly in patients at high fracture risk.

Teriparatide is FDA-approved for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis at high fracture risk, and men and women with glucocorticoid-induced osteoporosis at high fracture risk. Treatment duration is limited to 24 months cumulative lifetime due to preclinical findings of osteosarcoma in rats given very high doses over extended periods -- a risk that has not been demonstrated in human clinical trials.

Research Supply

Source high-purity Teriparatide for your research

Buy Teriparatide
Protocol

Dosage Guide

Route: Subcutaneous injection, once daily

Dosing Schedule

PeriodDose
Postmenopausal osteoporosis20 mcg once daily SQ (maximum 24 months lifetime)
Male osteoporosis (primary or hypogonadal)20 mcg once daily SQ (maximum 24 months lifetime)
Glucocorticoid-induced osteoporosis20 mcg once daily SQ (maximum 24 months lifetime)

Reconstitution

VIAL SIZESupplied as pre-filled injection pen (28-dose, 2.4 mL) -- no reconstitution required
WATER VOLUMEN/A (pre-filled pen in sterile solution)
CONCENTRATION250 mcg/mL
Each 20 mcg dose = 0.08 mL from the pre-filled pen

Injection Volumes

DoseVolumeSyringe Units
20 mcg0.08 mLFixed dose -- pen auto-delivers 20 mcg per actuation

Administration Tips

  • The first injection should be administered while the patient is sitting or lying down -- transient orthostatic hypotension may occur
  • Standard injection sites are the thigh and abdominal wall; rotate sites with each injection
  • The injection pen should be refrigerated at all times -- do not freeze
  • After removing from the refrigerator, allow the pen to reach room temperature before injecting
  • Following teriparatide cessation, transition to an antiresorptive therapy (such as a bisphosphonate) is recommended to preserve BMD gains
  • Treatment is typically reserved for patients at high or very high fracture risk due to the 24-month lifetime use limit
  • Higher doses did not produce superior BMD outcomes and increased side effect rates in dose-response studies
Safety

Risks & Side Effects

Commonly Reported

Nausea (approximately 8-18% of patients; usually mild and early in treatment)Dizziness and leg cramps, particularly within the first few hours after injectionOrthostatic hypotension (transient blood pressure drop shortly after injection, especially with first dose)Injection site reactions (redness, swelling, bruising, pain -- typically mild)Mild hypercalcemia (teriparatide increases calcium release from bone; serum calcium should be monitored)Arthralgia (joint pain) during longer-term useElevated serum uric acid levels (hyperuricemia without gout in some studies)

Serious Risks

Osteosarcoma

A black box warning exists based on rat carcinogenicity studies showing osteosarcoma at doses 3 to 60 times the human equivalent dose over the rat lifetime. No cases of osteosarcoma attributable to teriparatide have been confirmed in human clinical trials or post-marketing data, but the theoretical risk informs the 24-month lifetime use restriction.

Hypercalcemia

Clinically significant elevations in serum calcium can occur, particularly in patients with pre-existing conditions predisposing to hypercalcemia (hyperparathyroidism, Paget's disease).

Urolithiasis

Kidney stone formation; pre-existing nephrolithiasis is a relative contraindication.

Related Research

Related Peptides

Expert Voices

Experts Covering Teriparatide

Dr. William A. Seeds

MD -- Regenerative Medicine Pioneer

Dr. Ian W. Hamley

Diamond Professor of Physical Chemistry -- University of Reading

LEGAL DISCLAIMER

The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Teriparatide is FDA-approved under specific brand names for specific indications; use outside those approved indications may be off-label. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.

Frequently Asked Questions

What is Teriparatide and is it FDA approved?
Teriparatide is the recombinant form of the first 34 amino acids of human parathyroid hormone and the only FDA-approved anabolic bone-building agent for osteoporosis. Available as Forteo and Bonsity, it stimulates osteoblasts to form new bone rather than just slowing bone loss like bisphosphonates.
How effective is Teriparatide for osteoporosis?
In the pivotal trial of 1,637 postmenopausal women, 20 mcg daily teriparatide reduced new vertebral fracture risk by 65% [1] and nonvertebral fracture risk by 53% over 21 months. Lumbar spine bone mineral density increased by 9% and femoral neck BMD by 3%, demonstrating substantial clinical benefit.
Why is Teriparatide limited to 24 months?
The 24-month cumulative lifetime treatment limit exists because rat studies showed osteosarcoma at high doses over extended periods. No cases of osteosarcoma attributable to teriparatide have been confirmed in human trials or post-marketing data, but the theoretical risk informs this precautionary restriction.
What are Teriparatide side effects?
Common side effects include nausea (8 to 18% of patients), dizziness, leg cramps, orthostatic hypotension especially with the first dose, injection site reactions, mild hypercalcemia, and joint pain. The first injection should be given while sitting or lying down to prevent falls from blood pressure drops.
What happens when you stop Teriparatide?
Bone mineral density gains from teriparatide can be lost after discontinuation. Transitioning to an antiresorptive therapy such as a bisphosphonate after completing the teriparatide course is recommended to preserve the bone density gains achieved during the anabolic treatment phase.
How is Teriparatide administered?
Teriparatide is supplied as a pre-filled injection pen delivering a fixed 20 mcg dose per actuation. It is injected subcutaneously once daily into the thigh or abdominal wall, with site rotation. The pen must be refrigerated at all times and should never be frozen.

References

  1. Neer RM, Arnaud CD, Zanchetta JR, et al.. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001. PMID 11346808
  2. Saag KG, Shane E, Boonen S, et al.. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007. PMID 18003959
  3. Body JJ, Gaich GA, Scheele WH, et al.. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002. PMID 12364430

Regulatory & Official Sources